Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe

Abstract Background: Subcutaneous specific immunotherapy (SCIT) is claimed to be successful both in the US and Europe, yet treatment methodology differs. Methods: The authors review current literature surrounding guidelines and clinical trials in Europe and the US and contrast the treatment approach to SCIT for allergic rhinitis. Search methodology employs MEDLINE and PubMed, selecting articles on SCIT and allergic rhinitis, limited between 1990–2009. They focus on the safety and efficacy of vaccines, and the differences in formulations. Also mentioned are: standardization, new approaches in SCIT and sublingual immunotherapy (SLIT). Results: SCIT treatment differs in many respects regarding availability of SCIT products, regulatory controls, guidelines (e.g. multiple allergen vaccines in US, single allergen vaccines in Europe) and in location of formulation (US, clinician’s office; Europe, manufacturers). Conclusions: SCIT is an effective and safe therapy, but major evidence for efficacy is provided from European studies of single allergen extract vaccines; these vaccines may gain more acceptance because of increasing regulatory approval and lower numbers of injections. The potential impact upon public health (e.g. arrest of the ‘allergic march’) should not be overlooked.

[1]  C. Rhee,et al.  Sublingual immunotherapy in allergic rhinitis , 2011, Asia Pacific allergy.

[2]  S. Durham,et al.  Sublingual immunotherapy for allergic rhinitis , 2010 .

[3]  M. Rottem.  [Allergic rhinitis and its impact on asthma]. , 2010, Harefuah.

[4]  L. Cox,et al.  Comparison of allergen immunotherapy practice patterns in the United States and Europe. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  T. Casale,et al.  Significant Reduction In Combined Symptom And Medication Score Compared With Placebo With A Ragweed uSCIT Formulation For Seasonal Pollen Allergy , 2009 .

[6]  R. Van Ree,et al.  The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. , 2008, The Journal of allergy and clinical immunology.

[7]  S. Spector,et al.  The diagnosis and management of rhinitis: an updated practice parameter. , 2008, The Journal of allergy and clinical immunology.

[8]  J. Bousquet,et al.  Allergic rhinitis management pocket reference 2008 * , 2008, Allergy.

[9]  S. Durham,et al.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. , 2008, The Journal of allergy and clinical immunology.

[10]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[11]  D. Larenas-Linnemann,et al.  European allergen extract units and potency: review of available information. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  D. Ryan,et al.  BSACI guidelines for the management of allergic and non‐allergic rhinitis , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  S. Durham,et al.  Effect of grass pollen immunotherapy with Alutard SQ® on quality of life in seasonal allergic rhinoconjunctivitis , 2007, Allergy.

[14]  W. Keller,et al.  Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy , 2007, International Archives of Allergy and Immunology.

[15]  S. Spector,et al.  Allergen immunotherapy: a practice parameter third update. , 2007, The Journal of allergy and clinical immunology.

[16]  Joint Task Force on Practice Parameters.  Allergen immunotherapy: a practice parameter second update. , 2007 .

[17]  H. Renz,et al.  Epidemiological and immunological evidence for the hygiene hypothesis. , 2007, Immunobiology.

[18]  M. Larché,et al.  Update on the current status of peptide immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[19]  A. Williams,et al.  Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. , 2007, European annals of allergy and clinical immunology.

[20]  J Bousquet,et al.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce , 2007, Allergy.

[21]  A. Sheikh,et al.  Allergen injection immunotherapy for seasonal allergic rhinitis. , 2007, The Cochrane database of systematic reviews.

[22]  P. Patel,et al.  Pollinex® Quattro: a novel and well–tolerated, ultra short–course allergy vaccine , 2006, Expert review of vaccines.

[23]  R. Gerth van Wijk,et al.  Allergy and Clinical Immunology Services in Europe * , 2006, Allergy.

[24]  J. Bousquet,et al.  Standards for practical allergen‐specific immunotherapy , 2006, Allergy.

[25]  A. Mari,et al.  Allergenic Extracts for Specific Immunotherapy: To Mix or Not to Mix? , 2006, International Archives of Allergy and Immunology.

[26]  G. Canonica,et al.  Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[27]  A. Fiocchi,et al.  Food allergy and the introduction of solid foods to infants: a consensus document. Adverse Reactions to Foods Committee, American College of Allergy, Asthma and Immunology. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  S. Durham,et al.  IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. , 2006, Immunology and allergy clinics of North America.

[29]  L. Cox,et al.  Sublingual immunotherapy: a comprehensive review. , 2006, The Journal of allergy and clinical immunology.

[30]  S. Durham,et al.  Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[31]  D. Price,et al.  International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. , 2006, Primary care respiratory journal : journal of the General Practice Airways Group.

[32]  A. D'souza,et al.  Immunotherapy for allergic rhinitis – a United Kingdom survey and short review , 2005, The Journal of Laryngology & Otology.

[33]  M. Jutel,et al.  Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.

[34]  M. Carmona,et al.  Double‐blind and placebo‐controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma , 2005, Allergy.

[35]  A. Narkus,et al.  Efficacy and safety of preseasonal‐specific immunotherapy with an aluminium‐adsorbed six‐grass pollen allergoid , 2005, Allergy.

[36]  M. Contoli,et al.  Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study. , 2005, European annals of allergy and clinical immunology.

[37]  S. Durham,et al.  Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis * , 2005, Allergy.

[38]  S. Durham,et al.  Prevalence and rate of diagnosis of allergic rhinitis in Europe , 2004, European Respiratory Journal.

[39]  A. Wheeler,et al.  Allergy vaccines – new approaches to an old concept , 2004, Expert opinion on biological therapy.

[40]  C. Ortolani,et al.  Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double‐blind, placebo‐controlled study , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[41]  S. Durham,et al.  Mechanisms of immunotherapy. , 2004, The Journal of allergy and clinical immunology.

[42]  G. Liss,et al.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. , 2004, The Journal of allergy and clinical immunology.

[43]  D. Strachan,et al.  Burden of allergic disease in the UK: secondary analyses of national databases , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[44]  D-Y Wang,et al.  Management of allergic rhinitis: a common part of practice in primary care clinics , 2004, Allergy.

[45]  R. Pauwels,et al.  Airway IgG Counteracts Specific and Bystander Allergen-Triggered Pulmonary Inflammation by a Mechanism Dependent on FcγR and IFN-γ1 , 2003, The Journal of Immunology.

[46]  W. Storms.  Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[47]  M. Blaiss.  Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. , 2003, Allergy and asthma proceedings.

[48]  Shelby D Reed,et al.  Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. , 2003, The Journal of allergy and clinical immunology.

[49]  J. Bousquet,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) , 2003 .

[50]  D. Nowak,et al.  Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1‐yr retrospective study , 2003, European Respiratory Journal.

[51]  H. Malling,et al.  The safety and efficacy of subcutaneous birch pollen immunotherapy – a one‐year, randomised, double‐blind, placebo‐controlled study , 2002, Allergy.

[52]  S. Guerra,et al.  Rhinitis as an independent risk factor for adult-onset asthma. , 2002, The Journal of allergy and clinical immunology.

[53]  R. Sly.  Epidemiology of allergic rhinitis , 2002, Clinical reviews in allergy & immunology.

[54]  J. Bousquet,et al.  Pro: Immunotherapy is clinically indicated in the management of allergic asthma. , 2001, American journal of respiratory and critical care medicine.

[55]  P. Cauwenberge,et al.  Consensus statement on the treatment of allergic rhinitis (European Academy of Allergology and Clinical Immunology) , 2001 .

[56]  David Skoner,et al.  Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. , 2001, The Journal of allergy and clinical immunology.

[57]  S. Durham,et al.  Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. , 2001, The Journal of allergy and clinical immunology.

[58]  F. Horak,et al.  A well‐tolerated grass pollen‐specific allergy vaccine containing
a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections , 2001, Allergy.

[59]  H. Pillsbury,et al.  Allergy Testing and Immunotherapy in an Academic Otolaryngology Practice: A 20-year Review , 2001, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[60]  M. J. Derebery,et al.  Allergy and Health-Related Quality of Life , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[61]  J Bousquet,et al.  Consensus statement * on the treatment of allergic rhinitis , 2000, Allergy.

[62]  R. Puy,et al.  Immunotherapy in asthma: an updated systematic review , 1999, Allergy.

[63]  R. Platt,et al.  Utilization and cost of immunotherapy for allergic asthma and rhinitis. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[64]  S. Spector,et al.  Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[65]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[66]  L. Klimek,et al.  Tree‐pollen allergy is efficiently treated by short‐term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens , 1998, Allergy.

[67]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[68]  Richard Beasley,et al.  Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC , 1998, The Lancet.

[69]  Davis,et al.  Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[70]  D. Jarvis,et al.  The epidemiology of allergic disease , 1998 .

[71]  G. Rasp,et al.  Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[72]  J. Tonascia,et al.  A controlled trial of immunotherapy for asthma in allergic children. , 1997, The New England journal of medicine.

[73]  C. Martínez-Cócera,et al.  A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy , 1996, Allergy.

[74]  G. Senna,et al.  Safety of specific immunotherapy: a retrospective study. , 1994, Journal of investigational allergology & clinical immunology.

[75]  E. Pastorello,et al.  A double‐blind, placebo‐controlled study of immunotherapy with an alginate‐conjugated extract of Parietaria Judaica in patients with Parietaria hay fever , 1994, Allergy.

[76]  D. Umetsu,et al.  Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals , 1993, The Journal of experimental medicine.

[77]  J. Janosky,et al.  Compliance with allergen immunotherapy. , 1993, Annals of allergy.

[78]  J. Cohn,et al.  Determinants of patient compliance with allergen immunotherapy. , 1993, The Journal of allergy and clinical immunology.

[79]  A. Woolcock,et al.  A scale for the measurement of quality of life in adults with asthma. , 1992, Journal of clinical epidemiology.

[80]  G. Russell,et al.  Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart. , 1992, BMJ.

[81]  S. Durham,et al.  Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. , 1991, BMJ.

[82]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. , 1990, The Journal of allergy and clinical immunology.

[83]  E. Pastorello,et al.  Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. , 1984, The Journal of allergy and clinical immunology.

[84]  J. Freeman.  FURTHER OBSERVATIONS ON THE TREATMENT OF HAY FEVER BY HYPODERMIC INOCULATIONS OF POLLEN VACCINE. , 1911 .

[85]  L. Noon.  Prophylactic inoculation against hay fever. , 1911, International archives of allergy and applied immunology.

[86]  S. Durham,et al.  Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. , 2008, Clinical allergy and immunology.

[87]  E. Meltzer,et al.  Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. , 2008, The Journal of allergy and clinical immunology.

[88]  I. Bernstein.  Allergen immunotherapy: a practice parameter second update. , 2007, The Journal of allergy and clinical immunology.

[89]  E. Enrique,et al.  Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. , 2005, Journal of investigational allergology & clinical immunology.

[90]  L. Bernstein,et al.  Allergen immunotherapy: a practice parameter , 2003 .

[91]  C. Bachert,et al.  The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. , 2003, Chemical immunology and allergy.

[92]  Joint Task Force on Practice Parameters.  Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[93]  S. Durham,et al.  Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. , 2001, The Journal of allergy and clinical immunology.

[94]  P. Z. Brewczynski,et al.  WIRKSAMKEIT UND VERTRAGLICHKEIT EINER IMMUNTHERAPIE MIT MODIFIZIERTEN GRASERPOLLENALLERGENEN : ERGEBNISSE EINER PLAZEBOKONTROLLIERTEN STUDIE , 1999 .

[95]  M. Grieco,et al.  The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. , 1986, Annals of allergy.